FibroScan by Echosens

A rapid, non-invasive, point of care liver examination.

What is FibroScan?

FibroScan is a non-invasive technology that quickly provides a quantitative assessment of liver stiffness and liver fat at the point of care. As part of an overall patient assessment, FibroScan-based scores can be used to efficiently rule out the need for further assessment, like a painful liver biopsy, saving time and resources for people who do not require additional assessment for end-stage liver disease.

Different styles to support
your evolving needs

The FibroScan technology is available in different styles to support your evolving needs: FibroScan Compact, FibroScan mini. Every member of the FibroScan product family uses the same dual function technology, designed to guide the operator through the examination, to provide consistent, reliable results irrespective of system and operator.

How does FibroScan work

Dual function

Only FibroScan can provide dual function liver testing: Echosens patented VCTE™ and CAP™ assessments. These are simultaneously acquired during a simple, painless and time-efficient examination. Together, VCTE and CAP provide important information to assess your patients' liver health.

FibroScan 530 Compact

Liver stiffness assessment

  • Quantification of the liver stiffness with no image provided.
  • Large three cubic centimeters explored volume compensates for liver tissue heterogeneity. Exploration volume of three cubic centimeters is over 100x bigger than with needle biopsy1
  • Mechanically induced 50 Hz shear wave. Shear wave speed measured with pulse echo ultrasound
  • Liver stiffness calculated and expressed as a median over minimum 10 measurements
  • Median measured in Kilopascals (KPa)

Download the VCTE
white paper

Learn more about VCTE and the FibroScan ecosystem

Download To Learn More About VCTE

What is CAP™?

In addition to VCTE, FibroScan calculates the ultrasound attenuation rate within the same explored 3cm3 volume. This assessment, known as CAP, is associated with the level of fat present in the liver tissue. During the measurement, an ultrasound is generated by the FibroScan probe, the CAP measurement calculates the absorption or attenuation of this ultrasound. As fat builds up in the liver, the attenuation rate increases.

Take a closer look at the CAP technology

Fat approximation (CAP)

  • Large three cubic centimeters explored volume
  • CAP is computed from the pulse echo ultrasound signal used in VCTE
  • CAP calculated and expressed as a median over minimum 10 measurements
  • CAP is expressed in decibel per meter (db/m)
FibroScan exam probes in small, medium, and extra large


Different FibroScan Probes for Different Patient Types

To optimize measurement accuracy and consistency, FibroScan offers a range of probe models that match the measurement area of most patient morphology. By adjusting the measurement area relative to the distance of the liver below the surface of the skin, a consistent  three cubic centimeters explored volume can be maintained.

  • S+ Probe, Pediatric: Designed for pediatric patients with a thoracic perimeter less than 75cm
  • M+ Probe, Medium: Designed for adults in which the distance from the skin to the liver capsule is 25mm or less.
  • XL+ Probe, Extra Large: Designed for heavier weight adults in which the distance from the skin to the liver capsule is over 35mm.

Fibroscan results

Operated by an Echosens certified operator, FibroScan provides instantaneous quantitative results at the end of the examination. The treating healthcare professional will interpret these measurements based on the etiology and guidelines of their preference. With the MyFibroScan app, physicians can enter their patient’s scores, select their etiology and view a graphical representation of their patients’ scores compared to the threshold cutoff values of the selected etiology.

Learn more by downloading the app
FibroScan interpretation guidelines as shown on cell phone

FibroScan is FDA cleared

FDA Statement

FibroScan is the first and only point of care device specifically developed and FDA cleared as an aid to the diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver. The FibroScan accuracy has been extensively studied and is the reference for many major treatment guidelines.

The intended use/indications for use for the FibroScan are as follows:

The FibroScan family of products (models:502 Touch, 530 Compact, and 430 Mini+) is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body.

FibroScan Family of Products (Models: 502 Touch, 530 Compact, and 430 mini +) is indicated for noninvasive measurement in the liver of 50Hz shear wave speed and estimates of stiffness as well as 3.5Mhz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter).

The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.

Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.

Additionally, FibroScan technology complies with all applicable rules governing the level of energy applied and absorbed to the human body, including mechanical indexes and heat dissipation.

Current media

October 19, 2020 in All, Blog

Rise of Liver Cancer Rates and Link to Non-alcoholic Fatty Liver Disease Highlight Importance of Early Detection

Join us in supporting October 2020 Liver Cancer Awareness Month In the spirit of Liver Cancer Awareness Month this October, Echosens would like to highlight some alarming trends to help…
Read More
September 15, 2020 in Blog

FibroScan and Chronic Care Liver Disease Management

Self-Insured Employers Can Boost Workforce Productivity, Reduce Medical Costs   Download our latest white paper: “Comprehensive Chronic Care Disease Management of Liver Disease Improves Member Outcomes, Reduces Costs for Employer-…
Read More
September 14, 2020 in Blog

Economic Analysis Model Suggests Screening People for Fibrosis With Non-Invasive Tests Cost-effective

NASH Network (NASHNET), a global network of thought leaders dedicated to advancing care pathways for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), has published a novel cost-effectiveness analysis…
Read More

Contact a representative

In North America there are over 1200+ FibroScan systems in operation & we’re growing!

Speak to a Representative
  1. Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, Bahr MJ. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver International 2009;29:1500-1506.